Alterity Therapeutics Limited, a development stage enterprise, has announced the application for quotation of securities on April 15, 2024. The company, listed under the ticker ATH on the ASX, is seeking to quote a total of 285,087,715 options expiring on August 31, 2026. These options, identified with the security code ATHO, were issued as part of a transaction previously announced on February 23, 2024. The options are being issued without cash consideration; instead, they are attached to placement shares issued per the placement announcement made earlier in February. Following the quotation, Alterity Therapeutics' issued capital will include over 5 billion ordinary fully paid shares and a variety of option classes with different expiration dates and exercise prices.

Alterity Therapeutics Limited, a development stage enterprise, has announced the application for quotation of securities on April 15, 2024. The company, listed under the ticker ATH on the ASX, is seeking to quote a total of 285,087,715 options expiring on August 31, 2026. These options, identified with the security code ATHO, were issued as part of a transaction previously announced on February 23, 2024. The options are being issued without cash consideration; instead, they are attached to placement shares issued per the placement announcement made earlier in February. Following the quotation, Alterity Therapeutics' issued capital will include over 5 billion ordinary fully paid shares and a variety of option classes with different expiration dates and exercise prices.